Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-03-2012 | Original Article

Hematological Malignancies in Al-Amal Oncology Unit, Aden

Author: Waiel Al-Kahiry

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2012

Abstract

The hematological malignancies (HM) are group of neoplasms that arise through malignant transformation of bone marrow derived cells. The great diversity seen in this group of disorders is a reflection of the complexity of normal hematopoiesis and the immune system. In the current study, the author retrospectively studied HM patients from 2008 to 2010, and compared with prevalence of solid tumor, and found HM represented one-fifth of all malignancies managed in the Oncology Unit, and lymphomas were the commonest HM.

Oslen JH (2005) Epidemiology of hematological malignancies. In: Degos L, Linch DC, Löwenberg B (eds) Textbook of malignant hematology, 2nd edn. Taylor and Francis Group, London, pp 466–481

Jemal A, Murray T, Samuels A (2003) Cancer statistics. CA Cancer J Clin 53:5–26PubMedCrossRef

Lichtman MA (2008) Battling the hematological malignancies: the 200 years’ war. Oncologist 13(2):126–138PubMedCrossRef

Rodriguez-Abreu D, Bordoni A, Zucca E (2007) Epidemiology of hematological malignancies. Ann Oncol 18(Supplement 1):i3–i8PubMedCrossRef

Mashhadi MA, Zakeri Z, Abdollahinejad MJ (2010) Cancer incidence in south east of Iran: results of a population-based cancer registry. Shiraz E-Med J 11(3). Available from: http://semj.sums.ac.ir/vol11/jul2010/88023.htm. Accessed on October 2010

Babatunde A, Amiwero C, Olatunji P, Durotoye I (2009) Pattern of haematological malignancies in Ilorin, Nigeria: a ten year review. Internet J Haematol 5(2). Available from: http://www.ispub.com/journal/the_internet_journal_of_hematology/volume_5_number_2_44/article/pattern_of_haematological_malignancies_in_ilorin_nigeria_a_ten_year_review.html. Accessed on October 2010

Ba Saleem HO, Bawazir AA, Moore M, Al-Sakkaf KA (2010) Five years cancer incidence in Aden cancer registry, Yemen (2002–2006). Asian Pac J Cancer Prev 11:507–511PubMed

Wegman-Ostrosky T, Candelaria M, Duenas-Gonzalez A (2007) Epigenetic and hematological malignancies. Cancerología 2:159–170

Al-Ahwal MS, Al-Sayws F, Johar I (2005) Febrile neutropenia comparison between solid tumours and hematological malignancies. Pan Arab Med J 4:4–7

10.

McNally RJ, Rowland D, Roman E, Cartwright RA (1997) Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 15(4):173–189PubMedCrossRef

11.

Bahammam AS, Basha SJ, Masood MI, Shaik SA (2005) Outcome of patients with hematological malignancies admitted to the intensive care unit with life-threatening complications. Saudi Med J 26(2):246–250PubMed

12.

Broccia G, Deplano W, Dessalvi P, Giannico B, Luxi G, Chessa E, Murru A (2004) Hematological malignancies in the Island of Sardinia, 1974–1993: age and sex distributions and temporal changes in incidence. Hematol Oncol 22:91–109PubMedCrossRef

13.

Broccia G, Gabbas A, Longinotti M (2005) Newly diagnosed cases of hematologic malignancies in Sardinia in the early 2000s: an estimation of their number, age and geographic distribution on the basis of a previous epidemiologic survey. Haematologica 90(3):429–430PubMed

14.

Besson C, Gonin C, Brebion A, Delaunay C, Panelatti G, Plumelle Y (2001) Incidence of hematological malignancies in Martinique, French West Indies, over representation of multiple myeloma and adult T cell leukemia/lymphoma. Leukemia 15(5):828–831PubMedCrossRef

15.

Kyle RA, Greipp PA (1988) Plasma cell dyscrasias: current status. Crit Rev Oncol Hematol 8(2):93–152PubMedCrossRef

16.

The Central Intelligence Agency (CIA) The World Factbook Publications. Life expectancy at birth. https://www.cia.gov/library/publications/the-world-factbook/fields/2102.html. Accessed on 3 Nov 2010

Title: Hematological Malignancies in Al-Amal Oncology Unit, Aden
Author: Waiel Al-Kahiry
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 1/2012
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-011-0101-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Peripheral Blood Mononuclear Cell Membrane Fluidity and Disease Outcome in Patients with Multiple Sclerosis

Persistently Elevated Laboratory Markers of Thrombosis and Fibrinolysis After Clinical Recovery in Malaria Points to Residual and Smouldering Cellular Damage

Pure Red Cell Aplasia in Systemic Onset Juvenile Idiopathic Arthritis

Prevalance of Iron Deficiency in Thalassemia Minor: A Study from Tertiary Hospital

Falsely Reported Malaria Parasites in Otherwise Normal Peripheral Blood Smears

Vascular Endothelial Growth Factor Levels in Childhood Acute Lymphoblastic and Myeloblastic Leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer